Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Trial details
- Registry ID
- NCT06747858
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisNCT06747858 | Arcturus Therapeutics, Inc. | Phase 2 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |